| Kiniksa Pharmaceuticals: Making Steady Progress |
Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimistic, with firms like Goldman Sachs, Wedbush, and Jefferies assigning Buy ratings and price targets ranging from $32 to $45 on the shares. Kiniksa also has a solid balance sheet with nearly $270 million in cash and no long-term debt. |
seekingalpha.com |
2025-05-05 20:51:16 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis |
– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed – |
globenewswire.com |
2025-04-30 12:30:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript |
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman & Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Mary Kate - Citi Roger Song - Jefferies Eva Fortea-Verdejo - Wells Fargo Anupam Rama - JPMorgan David Nierengarten - Wedbush Operator Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-04-29 19:07:03 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates |
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share. |
zacks.com |
2025-04-29 13:36:06 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution |
– ARCALYST ® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today – |
globenewswire.com |
2025-04-29 11:30:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 |
LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. |
globenewswire.com |
2025-04-24 20:01:00 |
Czytaj oryginał (ang.) |
| Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year? |
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far this year. |
zacks.com |
2025-04-08 14:40:35 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know |
The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-04-04 14:55:31 |
Czytaj oryginał (ang.) |
| How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6% |
The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-03-19 12:55:39 |
Czytaj oryginał (ang.) |
| 3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now |
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable. |
fool.com |
2025-03-14 07:51:00 |
Czytaj oryginał (ang.) |
| Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock |
Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-03-04 15:20:54 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock? |
Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2025-03-04 06:05:34 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High? |
The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-03-03 12:55:54 |
Czytaj oryginał (ang.) |
| Big Pipeline Updates From Kiniksa Pharmaceuticals |
Big Pipeline Updates From Kiniksa Pharmaceuticals |
seekingalpha.com |
2025-02-25 18:14:06 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript |
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript |
seekingalpha.com |
2025-02-25 12:53:41 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates |
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.06. |
zacks.com |
2025-02-25 11:45:33 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution |
– ARCALYST ® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – Abiprubart development in Sjögren's Disease to be discontinued – – Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today – |
globenewswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy |
– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 – – KPL-387 Phase 1 single ascending dose data support potential monthly dosing – – Kiniksa continues to focus development on diseases with unmet need, prioritizing cardiovascular indications – – Kiniksa to discontinue abiprubart development in Sjögren's Disease – LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced the development program for KPL-387 in recurrent pericarditis and provided an update on its corporate strategy. KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling activity of the cytokines interleukin-1α (IL-1α) and interleukin-1β (IL-1β). |
globenewswire.com |
2025-02-25 09:29:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 |
LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution. |
globenewswire.com |
2025-02-20 18:01:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance |
– ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – Kiniksa expects to remain cash flow positive on an annual basis – |
globenewswire.com |
2025-01-13 09:30:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference |
LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). |
globenewswire.com |
2025-01-06 18:01:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference |
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time. |
globenewswire.com |
2024-11-26 18:01:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference |
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:00 p.m. Greenwich Mean Time (7:00 a.m. Eastern Time). |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript |
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman and Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Liisa Bayko - Evercore ISI Paul Choi - Goldman Sachs Eva Fortea-Verdejo - Wells Fargo David Nierengarten - Wedbush Securities Anupam Rama - JPMorgan Operator Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-10-29 13:45:28 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates |
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.01. |
zacks.com |
2024-10-29 11:46:09 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution |
– ARCALYST ® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY ® Award-winning singer-songwriter, Carly Pearce – – Kiniksa expects to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today – |
globenewswire.com |
2024-10-29 09:30:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 |
LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution. |
globenewswire.com |
2024-10-22 20:01:00 |
Czytaj oryginał (ang.) |
| What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing' |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-10-11 13:51:59 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet |
The consensus price target hints at a 42.3% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-10-09 14:56:27 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals (KNSA) is on the Move, Here's Why the Trend Could be Sustainable |
Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2024-09-20 13:56:09 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference |
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 8:00 a.m. Eastern Time. |
globenewswire.com |
2024-08-28 20:01:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade |
The consensus price target hints at a 30.1% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-08-05 15:01:17 |
Czytaj oryginał (ang.) |
| 5 Stocks With Recent Price Strength in a Volatile Market |
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are KNSA, HNI, AEYE, BCPC, GRC. |
zacks.com |
2024-08-02 12:22:06 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for August 1st |
CVNA, QCRH, and KNSA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 1, 2024. |
zacks.com |
2024-08-01 15:15:21 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for August 1st |
NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024. |
zacks.com |
2024-08-01 12:21:07 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know |
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors? |
zacks.com |
2024-07-26 17:01:25 |
Czytaj oryginał (ang.) |
| Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why |
Kiniksa Pharmaceuticals (KNSA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-07-26 13:51:32 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat |
Kiniksa Pharmaceuticals surged after the company reported strong second quarter results and increased the full year net sales guidance range for Arcalyst. The strong performance is driven by increased demand following the recent sales force expansion. The improved outlook for Arcalyst warrants an increase in the valuation range. |
seekingalpha.com |
2024-07-24 09:38:58 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates |
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. |
zacks.com |
2024-07-23 13:35:59 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024 |
LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution. |
globenewswire.com |
2024-07-16 20:01:00 |
Czytaj oryginał (ang.) |
| Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's Disease |
– Abiprubart Phase 2b clinical trial in Sjögren's Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations – |
globenewswire.com |
2024-07-09 12:00:00 |
Czytaj oryginał (ang.) |